研究晚期糖基化终末产物可溶性受体（sRAGE）通路在主动脉疾病中的原因。
Reasons to Investigate the Soluble Receptor for Advanced Glycation End-Product (sRAGE) Pathway in Aortic Disease.
作者信息
Sarkar Abdullah, Prasad Kailash, Ziganshin Bulat A, Elefteriades John A
机构信息
Department of Physiology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; and.
Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut;
出版信息
Aorta (Stamford). 2013 Aug 1;1(3):210-7. doi: 10.12945/j.aorta.2013.13-047. eCollection 2013 Aug.
Abstract
Aortic disease has a high rate of morbidity and mortality, and there are no documented screening methods to date. Yet biochemical research does show a significant link between soluble receptor for advanced glycation end-products (sRAGE) protein and cardiovascular disease. Therefore, it can be hypothesized that sRAGE plasma levels may help differentiate patients with aortic disease from the general population, which this paper will review and present.
摘要
主动脉疾病具有较高的发病率和死亡率，且迄今为止尚无经证实的筛查方法。然而，生化研究确实表明晚期糖基化终产物可溶性受体（sRAGE）蛋白与心血管疾病之间存在显著联系。因此，可以推测sRAGE血浆水平可能有助于将主动脉疾病患者与普通人群区分开来，本文将对此进行综述并阐述。
相似文献
1
Reasons to Investigate the Soluble Receptor for Advanced Glycation End-Product (sRAGE) Pathway in Aortic Disease.
Aorta (Stamford). 2013 Aug 1;1(3):210-7. doi: 10.12945/j.aorta.2013.13-047. eCollection 2013 Aug.
2
High Plasma sRAGE (Soluble Receptor for Advanced Glycation End Products) Is Associated With Slower Carotid Intima-Media Thickness Progression and Lower Risk for First-Time Coronary Events and Mortality.
Arterioscler Thromb Vasc Biol. 2019 May;39(5):925-933. doi: 10.1161/ATVBAHA.118.312319.
3
Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases?
Mol Cell Biochem. 2019 Jan;451(1-2):139-144. doi: 10.1007/s11010-018-3400-2. Epub 2018 Jun 30.
4
Critical Appraisal of Advanced Glycation End Products (AGEs) and Circulating Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients.
Med Sci (Basel). 2018 May 22;6(2):38. doi: 10.3390/medsci6020038.
5
Association of soluble receptor for advanced glycation end-product with increasing central aortic stiffness in hypertensive patients.
Coron Artery Dis. 2012 Mar;23(2):85-90. doi: 10.1097/MCA.0b013e32834f114e.
6
Soluble receptor for advanced glycation end products in critically ill patients and its associations with other clinical markers and 28-day mortality.
Clin Interv Aging. 2014 Nov 19;9:1981-6. doi: 10.2147/CIA.S71130. eCollection 2014.
7
Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
Nephrol Dial Transplant. 2015 Jan;30(1):84-91. doi: 10.1093/ndt/gfu259. Epub 2014 Jul 28.
8
Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
Metabolism. 2018 Jun;83:120-127. doi: 10.1016/j.metabol.2018.01.023. Epub 2018 Feb 2.
9
Serum soluble receptor for advanced glycation end products correlates inversely with measures of adiposity in young adults.
Nutr Res. 2014 Jun;34(6):478-85. doi: 10.1016/j.nutres.2014.04.012. Epub 2014 Apr 24.
10
Soluble receptor for advanced glycation end products in male infertility.
Hippokratia. 2017 Jan-Mar;21(1):19-24.
引用本文的文献
1
Evaluation of a Classifier Based on Calprotectin Concentration and Advanced Glycation End-Product Receptor as a Potential Biomarker for Abdominal Aortic Aneurysm.
Int J Mol Sci. 2025 Aug 11;26(16):7752. doi: 10.3390/ijms26167752.
2
The Role of Advanced Glycation End-Products in the Pathophysiology and Pharmacotherapy of Cardiovascular Disease.
Int J Mol Sci. 2025 Jul 29;26(15):7311. doi: 10.3390/ijms26157311.
3
Relationship between the Levels of Calprotectin and Soluble Receptor for Advanced Glycation End Products with Abdominal Aortic Aneurysm Diameter: A Preliminary Clinical Trial.
J Clin Med. 2022 Sep 16;11(18):5448. doi: 10.3390/jcm11185448.
4
The Predictive Role of Plasma Biomarkers in the Evolution of Aortopathies Associated with Congenital Heart Malformations.
Int J Mol Sci. 2022 Apr 30;23(9):4993. doi: 10.3390/ijms23094993.
5
Calprotectin and Receptor for Advanced Glycation End Products as a Potential Biomarker in Abdominal Aortic Aneurysm.
J Clin Med. 2020 Mar 28;9(4):927. doi: 10.3390/jcm9040927.
6
The Association of Serum Thrombomodulin with Endothelial Injuring Factors in Abdominal Aortic Aneurysm.
Biomed Res Int. 2017;2017:2791082. doi: 10.1155/2017/2791082. Epub 2017 Apr 3.
7
Advanced Glycation End Products and its Soluble Receptors in the Pathogenesis of Thoracic Aortic Aneurysm.
Aorta (Stamford). 2016 Feb 1;4(1):1-10. doi: 10.12945/j.aorta.2015.15.018. eCollection 2016 Feb.
8
Circulating soluble receptor for advanced glycation end product identifies patients with bicuspid aortic valve and associated aortopathies.
Arterioscler Thromb Vasc Biol. 2014 Oct;34(10):2349-57. doi: 10.1161/ATVBAHA.114.303784. Epub 2014 Aug 14.
本文引用的文献
1
Reverse regulation of soluble receptor for advanced glycation end products and proinflammatory factor resistin and S100A12 in Kawasaki disease.
Arthritis Res Ther. 2012 Nov 21;14(6):R251. doi: 10.1186/ar4094.
2
Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients.
Int J Angiol. 2009 Winter;18(4):187-92. doi: 10.1055/s-0031-1278352.
3
Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure.
Curr Heart Fail Rep. 2012 Jun;9(2):107-16. doi: 10.1007/s11897-012-0089-5.
4
Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention.
Clin Cardiol. 2010 Nov;33(11):678-85. doi: 10.1002/clc.20815.
5
Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis.
Atherosclerosis. 2010 Jun;210(2):614-8. doi: 10.1016/j.atherosclerosis.2009.12.029. Epub 2010 Jan 4.
6
Cellular and molecular mechanisms of thoracic aortic aneurysms.
Nat Rev Cardiol. 2009 Dec;6(12):771-86. doi: 10.1038/nrcardio.2009.191. Epub 2009 Nov 3.
7
S100A12 mediates aortic wall remodeling and aortic aneurysm.
Circ Res. 2010 Jan 8;106(1):145-54. doi: 10.1161/CIRCRESAHA.109.209486. Epub 2009 Oct 29.
8
Levels of Soluble Receptor for Advanced Glycation End Products in Acute Ischemic Stroke without a Source of Cardioembolism.
J Clin Neurol. 2009 Sep;5(3):126-32. doi: 10.3988/jcn.2009.5.3.126. Epub 2009 Sep 30.
9
Low levels of plasma soluble receptor for advanced glycation end products are associated with severe leukoaraiosis in acute stroke patients.
J Neurol Sci. 2009 Dec 15;287(1-2):41-4. doi: 10.1016/j.jns.2009.09.013. Epub 2009 Oct 3.
10
Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm.
Ann Surg. 2009 Sep;250(3):416-23. doi: 10.1097/SLA.0b013e3181b41a18.
Zotero 插件